Evgeniy V. Bobykin

Evgeniy V. Bobykin

Auto-generated profile, based on publicly available information

Evgeniy V. Bobykin

Ural State Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2021 in Russian Ophthalmological Journal
Verified
Journal Article
Open access
PDF file
VNV. V. Neroev
V. V. Neroev
SKS. A. Korotkikh
S. A. Korotkikh
EBE. V. Bobykin
E. V. Bobykin
OZO. V. Zaytseva
O. V. Zaytseva
ALA. B. Lisochkina
A. B. Lisochkina
MSM. M. Shishkin
M. M. Shishkin
The widespread introduction of intravitreal drug injections into clinical practice has highlighted a number of issues to be solved, including the risk of serious complications, the treatment burden on patients and the patient’s insufficient adherence to treatment, as well as a significant effect on the healthcare cost and effort. One of the ways to resolve the issues is to increase the patients’ awareness concerning the therapy they are about to receive, which contributes to the patients’ understanding of the details of treatment and enables them to make correct decisions. The best option of presenting such information to the patient is to provide them with a written document. The Expert Council on Retinal and Optic Nerve Diseases of the All-Russian Association of Ophthalmologists has developed, approved and tested an information brochure for patients who receive intravitreal injections. It offers brief information on what the procedure is, contraindications, details of preparation, and symptoms, both common ones and those requiring emergency assistance. The paper outlines the results of the study and presents a layout of an information leaflet for patients recommended for use in the Russian Federation.

1 January 2022 in Russian Annals of Ophthalmology
Verified
Journal Article
Closed access
OZO.V. Zaytseva
O.V. Zaytseva
NNN.V. Neroeva
N.V. Neroeva
TOT.D. Okhotsimskaya
T.D. Okhotsimskaya
EBE.V. Bobykin
E.V. Bobykin
Повышение эффективности анти-VEGF-терапии неоваскулярной («влажной») возрастной макулярной дегенерации (нВМД) является одним из приоритетных направлений развития современной ретинологии, что обусловлено значительной медицинской и социальной значимостью этого заболевания. В статье изложены современные представления о патобиологии и клинических проявлениях «неполного ответа на анти-VEGF-терапию» нВМД. Кроме того, представлены опубликованные предложения по совершенствованию терминологии и классификации ответа на терапию, а также по оценке правильности и эффективности проводимого лечения. Обсуждаются имеющиеся пути оптимизации терапии и определения показаний к ее прекращению в случаях бесперспективности.

4 May 2023 in Russian Ophthalmological Journal
Verified
Journal Article
Open access
PDF file
VNV. V. Neroev
V. V. Neroev
OZO. V. Zaytseva
O. V. Zaytseva
ETE. P. Tarutta
E. P. Tarutta
EBE. V. Bobykin
E. V. Bobykin
MKM. A. Kovalevskaya
M. A. Kovalevskaya
PNP. A. Nechiporenko
P. A. Nechiporenko
Myopic refraction is the most common ocular pathology, currently affecting about 1.5 billion people worldwide. Recent decades have seen a trend towards a significant increase in myopia prevalence, which is likely to continue in the near future. Therefore, we observe some kind of an epidemic of myopia. The greatest concern is caused by cases of uncorrectable visual impairment associated with myopia, which make pathological (degenerative) myopia one of the leading causes of low vision and blindness in many countries. At the same time, there is still no uniform interpretation of such important concepts as “high myopia” and “pathological myopia”, which can negatively affect various aspects of clinical and scientific interaction among ophthalmologists. The article provides an overview of modern work on the above issues and proposes definitions of terms to be used in the healthcare system of the Russian Federation

14 June 2025 in Russian Ophthalmological Journal
Verified
Journal Article
Open access
PDF file
EBE. V. Bobykin
E. V. Bobykin
RFR. R. Fayzrakhmanov
R. R. Fayzrakhmanov
SGS. Yu. Golubev
S. Yu. Golubev
TDT. I. Dibaev
T. I. Dibaev
OZO. V. Zaytseva
O. V. Zaytseva
MSM. M. Shishkin
M. M. Shishkin
Disorders of the posterior segment of the eye are traditionally one of the most important medical and social problem. The rapid development in the ophthalmology field in the 20th and 21st centuries has led to a significant improvement in the knowledge on the physiology and pathology of the light-perceiving eye structures, revolutionary achievements in the diagnosis and treatment of a wide range of retinal diseases, optic nerve, choroid and vitreous body pathology. The need for highly qualified physicians with a modern understanding of this problem led to the emergence of an ophthalmological specialization called “retinology”. Modern retinology includes various areas of diagnostics (including visualization of eye structures, electrophysiological and genetic methods), as well as drug, laser and microsurgical treatment and rehabilitation of the patients. In the rapidly developing medicine, sociological research is extremely important, allowing health care organizers to assess existing trends and make decisions determining the development direction in the field, and specialists to exchange opinions and analyze their professional activities. Retinology is no exception. Surveys of professional organizations of retinologists that have great scientific and practical significance are successfully conducted abroad, the most famous of which are the EURETINA Clinical Trends Survey and the ASRS Preferences and Trends (PAT) Survey. In Russia, such surveys have not been conducted to date. At the same time, the opportunity to learn the opinions of Russian specialists, as well as to compare domestic and foreign data is of undoubted interest. In 2024, we organized and conducted the first independent Russian survey of retinologists “SETCHAtochkaRU”, in which 585 ophthalmologists from all federal districts of the Russian Federation took part, as well as our colleagues from Belarus, Kazakhstan, Kyrgyzstan, Latvia, Lebanon, Tajikistan, Turkmenistan, Turkey and Uzbekistan. The main results of the survey are presented in this publication.

4 January 2022 in Russian Ophthalmological Journal
Verified
Journal Article
Open access
PDF file
EBE. V. Bobykin
E. V. Bobykin
OMO. V. Morozova
O. V. Morozova
NBN. S. Beresneva
N. S. Beresneva
Macular diseases are traditionally a serious issue in ophthalmology, which has great social impact due to widespread occurrence and significant vision loss, often irreversible. Over the past few decades, the possibilities for the diagnosis and treatment of pathologies of the retina and choroid have been significantly expanded. Randomized clinical trials provided ophthalmologists with valuable information on the natural course and treatment strategies of common retinal diseases from the viewpoint of evidence-based medicine. However, due to the large number of trials conducted, it is often difficult to make an adequate choice of data to be used in daily practice. In this review, we systematize the most valuable randomized clinical trials. To this end, we selected 42 randomized clinical studies conducted between 1979 and 2019 and focused on the treatment of age-related macular degeneration (AREDS 1, AREDS 2, ANCHOR, MARINA, PrONTO, CATT, IVAN, VIEW 1, VIEW 2, EVEREST II, PLANET, SEVEN-UP, ALTAIR, HAWK, HARRIER), choroidal neovascularization of multiple etiology (myopic, post-inflammatory, angioid-streak-related, etc. — RADIANCE, REPAIR, MYRROR, MINERVA), diabetic eye lesions (diabetic retinopathy and diabetic macular edema — ETDRS, DRCR.net Protocols B, I, S and T, RISE, RIDE, VIVID-DME, VISTA-DME, MEAD, FAME), retinal vein occlusions (BVOS, CVOS, SCORE-CRVO, SCORE-BRVO, BRAVO, CRUISE, GALILEO, COPERNICUS, VIBRANT), as well as retinopathy of prematurity (CRYO-ROP, ETROP, RAINBOW). The review summarizes the main results of these studies, which confirm the effectiveness and safety of such treatment methods as antiVEGF and photodynamic therapy, retinal laser photocoagulation, cryotherapy, corticosteroids and nutraceuticals from the viewpoint of evidence-based medicine. For greater clarity, we provide a table summarizing information on each of the randomized clinical trials considered.

15 March 2020 in Russian Ophthalmological Journal
Verified
Journal Article
Open access
PDF file
SNS. V. Nedogoda
S. V. Nedogoda
ASA. S. Salasyuk
A. S. Salasyuk
EBE. V. Bobykin
E. V. Bobykin
IBI. N. Barykina
I. N. Barykina
VSV. O. Smirnova
V. O. Smirnova
EPE. A. Popova
E. A. Popova
Фармакоэкономическое исследование применения афлиберцепта у пациентов с «влажной» формой возрастной макулярной дегенерации